GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zomedica Corp (AMEX:ZOM) » Definitions » EPS without NRI

Zomedica (Zomedica) EPS without NRI : $-0.03 (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zomedica EPS without NRI?

Zomedica's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.03.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 21.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 38.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Zomedica's EPS without NRI or its related term are showing as below:

ZOM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -123.7   Med: 19.75   Max: 55.3
Current: 21.2

During the past 11 years, Zomedica's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 55.30% per year. The lowest was -123.70% per year. And the median was 19.75% per year.

ZOM's 3-Year EPS without NRI Growth Rate is ranked better than
65.91% of 704 companies
in the Medical Devices & Instruments industry
Industry Median: 8.9 vs ZOM: 21.20

Zomedica's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04.

Zomedica's EPS (Basic) for the three months ended in Mar. 2024 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04.


Zomedica EPS without NRI Historical Data

The historical data trend for Zomedica's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zomedica EPS without NRI Chart

Zomedica Annual Data
Trend Feb14 Feb15 Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.19 -0.05 -0.05 -0.02 -0.02

Zomedica Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - -0.01 -0.01

Competitive Comparison of Zomedica's EPS without NRI

For the Medical Devices subindustry, Zomedica's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zomedica's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Zomedica's PE Ratio without NRI falls into.



Zomedica EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zomedica  (AMEX:ZOM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Zomedica EPS without NRI Related Terms

Thank you for viewing the detailed overview of Zomedica's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Zomedica (Zomedica) Business Description

Traded in Other Exchanges
N/A
Address
100 Phoenix Drive, Suite 125, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.
Executives
Johnny D Powers director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Heaton Larry C Ii officer: President C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Russell Kevin Klass officer: Vice President of Sales C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Peter Donato officer: Chief Financial Officer 9172 ETON AVENUE, CHATSWORTH CA 91311
Pamela Nichols director 14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262
Karen Dehaan-fullerton officer: Chief Counsel and Secretary C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Anthony K Blair officer: Chief Operating Officer NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017
Adrian Lock officer: VP and General Manager C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Sean Whelan director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Robert Cohen officer: Interim CEO C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Ann Cotter officer: Chief Financial Officer & Sec. C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Stephanie Morley officer: COO & VP of Product Dev C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Christopher Ross Macleod director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Christopher Wolfenberg director C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Gerald Jr Solensky director, 10 percent owner, officer: President and CEO C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108